PETS International | Consolidation Meets Regulation in the Veterinary Clinics Market

Apr 2024

Originally posted by PETS International on April 5, 2024.

Animal health is becoming a big business in Europe and the U.S. Thus, regulators are turning a closer eye to mergers and acquisitions (M&A) activity.

Matt Lee, Managing Director and co-head of Lincoln’s European Healthcare Group, commented, “Regulation is now playing a growing role in the global veterinary market and influencing M&A, especially in Europe – most prominently in the UK and France. The US market is not immune either, with the Federal Trade Commission (FTC) imposing restrictions on the activities of Mars and JAB especially.”

These developments have led to a private equity comeback. This is beneficial for the sector as it expands the owner and future buyer base.

“One thing that has come out of the recent developments in Europe is the return to form of private equity over trade – perhaps a reflection of a moderation of valuation in the current high-interest environment and lesser competition from trade as balance sheets are repaired after years of aggressive deal making,” Matt said.

View additional insights in the original article.



Meet Professionals with Complementary Expertise in Healthcare

Related Perspectives in Healthcare

“Leader to Leader” Series

The Leader to Leader video series turns up the dial on rich conversations with prominent leaders – from business owners and entrepreneurs to investors and CEOs – highlighting their stories… Read More

What Price is Right? Trends and Opportunities for Private Equity in Pharma Market Access

The cost of developing new drugs is staggering. Among the top 20 global biopharmas, the average cost of developing a candidate from discovery through clinical trials to market was approximately… Read More

Investment Opportunities in Pharma: A Data-Driven Exploration of CDMO Appeal

The report discusses the current state of the contract development and manufacturing organization (CDMO) market within the pharmaceutical industry, emphasizing the increased interest from private equity (PE) investors. The pharmaceutical… Read More

Scrip Asks…What Does 2024 Hold for Biopharma?

James West, Managing Director in Lincoln’s Healthcare Group, recently discussed his expectations for the biopharma market in 2024 as part of Scrip’s series. Part One – Business Strategy and Leadership… Read More